SG10202004716RA - 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof - Google Patents

2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Info

Publication number
SG10202004716RA
SG10202004716RA SG10202004716RA SG10202004716RA SG10202004716RA SG 10202004716R A SG10202004716R A SG 10202004716RA SG 10202004716R A SG10202004716R A SG 10202004716RA SG 10202004716R A SG10202004716R A SG 10202004716RA SG 10202004716R A SG10202004716R A SG 10202004716RA
Authority
SG
Singapore
Prior art keywords
cdk
cyclin
inhibitors
therapeutic uses
dependent kinase
Prior art date
Application number
SG10202004716RA
Inventor
Michael Greco
Michael Costanzo
Jirong Peng
Victoria Wilde
Don Zhang
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of SG10202004716RA publication Critical patent/SG10202004716RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10202004716RA 2014-07-24 2015-07-24 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof SG10202004716RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028427P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
SG10202004716RA true SG10202004716RA (en) 2020-06-29

Family

ID=55163817

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700037QA SG11201700037QA (en) 2014-07-24 2015-07-24 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
SG10202004716RA SG10202004716RA (en) 2014-07-24 2015-07-24 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700037QA SG11201700037QA (en) 2014-07-24 2015-07-24 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Country Status (19)

Country Link
US (2) US9878994B2 (en)
EP (1) EP3191469B1 (en)
JP (1) JP6490215B2 (en)
KR (1) KR20170031241A (en)
CN (2) CN110117273B (en)
AP (1) AP2017009728A0 (en)
AU (1) AU2015292425B2 (en)
BR (1) BR112017001058A2 (en)
CA (1) CA2954298A1 (en)
CO (1) CO2017000912A2 (en)
EA (1) EA032693B1 (en)
IL (1) IL249895B (en)
MX (1) MX2017000806A (en)
MY (1) MY187555A (en)
PH (1) PH12017500146B1 (en)
SG (2) SG11201700037QA (en)
TW (1) TWI675028B (en)
WO (1) WO2016014904A1 (en)
ZA (1) ZA201700652B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110117273B (en) * 2014-07-24 2022-02-01 贝达医药公司 2H-indazole derivatives as Cyclin Dependent Kinase (CDK) inhibitors and their medical use
TWI696617B (en) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 Certain protein kinase inhibitor
CN106608879A (en) 2015-10-27 2017-05-03 甘李药业股份有限公司 Protein kinase inhibitor and its preparation method and medical application
CN108602799B (en) * 2016-02-06 2021-08-03 上海复尚慧创医药研究有限公司 Kinase inhibitor
WO2017160568A1 (en) * 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
CN107286134B (en) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2,4- disubstituted pyrimidines derivatives are as CDK inhibitor and its application
WO2018045993A1 (en) * 2016-09-09 2018-03-15 正大天晴药业集团股份有限公司 Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
ES2917377T3 (en) 2016-12-22 2022-07-08 Betta Pharmaceuticals Co Ltd Benzimidazole derivatives, preparation procedures and uses thereof
WO2018141296A1 (en) * 2017-02-06 2018-08-09 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators salt, crystallographic forms, and uses thereof
CN108794452B (en) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 Compound with kinase inhibition activity, preparation method and application thereof
TW201920141A (en) * 2017-08-15 2019-06-01 中國大陸商北京軒義醫藥科技有限公司 CDK4/6 inhibitors and use thereof
CN109503573A (en) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2- substituted anilinic pyrimidine derivatives and application thereof
MX2020007959A (en) * 2018-01-29 2020-09-18 Beta Pharma Inc 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof.
JP2021521282A (en) 2018-04-24 2021-08-26 上海海雁医薬科技有限公司Ｓｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． CDK4 / 6 inhibitors, their pharmaceutically acceptable salts and crystalline polymorphs, and their applications
RU2762557C1 (en) 2018-04-26 2021-12-21 Пфайзер Инк. Derivatives of 2-aminopyridine or 2-aminopyrimidine as cyclin-dependent kinase inhibitors
SG11202012312UA (en) * 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
EP3849537A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
JP2022519205A (en) * 2019-01-29 2022-03-22 ベータ・ファーマ・インコーポレイテッド 2H-indazole derivative as a therapeutic agent for brain tumors and brain metastases
SG11202109463PA (en) * 2019-03-20 2021-10-28 Beta Pharma Inc Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
WO2020224568A1 (en) * 2019-05-05 2020-11-12 Qilu Regor Therapeutics Inc. Cdk inhibitors
WO2021061695A1 (en) * 2019-09-23 2021-04-01 Beta Pharma, Inc. Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors
CN111100117B (en) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 Crystal form A of aminopyrimidine compound mesylate and preparation method and application thereof
CN113880816A (en) * 2020-07-01 2022-01-04 杭州百诚医药科技股份有限公司 Piperazine-containing aminopyrimidine derivative and application thereof
CN114539225B (en) * 2020-11-11 2024-02-20 上海拓界生物医药科技有限公司 2-amino-pyrimidines
TW202237585A (en) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN115703760A (en) * 2021-08-11 2023-02-17 山东大学 2,4-disubstituted pyrimidines cyclin dependent kinase inhibitor and preparation method and application thereof
CN115650968B (en) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 Novel pyridazinone compounds as CDK selective inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
ES2309368T3 (en) 2002-12-02 2008-12-16 F. Hoffmann-La Roche Ag DERIVATIVES OF INDAZOL AS AN ANTAGONIST OF CRF.
WO2006008874A1 (en) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON
WO2007124288A1 (en) * 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
JO3235B1 (en) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrrolopyrimidine compounds and their uses
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
CA2986640C (en) * 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2010034649A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
PA8852901A1 (en) * 2008-12-22 2010-07-27 Lilly Co Eli PROTEIN CINASE INHIBITORS
CN110117273B (en) * 2014-07-24 2022-02-01 贝达医药公司 2H-indazole derivatives as Cyclin Dependent Kinase (CDK) inhibitors and their medical use

Also Published As

Publication number Publication date
KR20170031241A (en) 2017-03-20
US9878994B2 (en) 2018-01-30
CO2017000912A2 (en) 2017-04-28
PH12017500146A1 (en) 2017-05-29
US20180148431A1 (en) 2018-05-31
US20170210726A1 (en) 2017-07-27
TWI675028B (en) 2019-10-21
ZA201700652B (en) 2019-12-18
PH12017500146B1 (en) 2017-05-29
CN110117273B (en) 2022-02-01
EP3191469A4 (en) 2018-03-21
MY187555A (en) 2021-09-29
TW201609705A (en) 2016-03-16
CN106687454B (en) 2019-06-21
CN106687454A (en) 2017-05-17
US10239864B2 (en) 2019-03-26
IL249895A0 (en) 2017-03-30
CN106687454B8 (en) 2019-08-30
EA201790122A1 (en) 2017-08-31
JP6490215B2 (en) 2019-03-27
EP3191469B1 (en) 2021-12-15
EP3191469A1 (en) 2017-07-19
BR112017001058A2 (en) 2018-06-26
IL249895B (en) 2020-03-31
AP2017009728A0 (en) 2017-01-31
AU2015292425A1 (en) 2017-02-16
AU2015292425B2 (en) 2018-12-20
JP2017522390A (en) 2017-08-10
CA2954298A1 (en) 2016-01-28
EA032693B1 (en) 2019-07-31
SG11201700037QA (en) 2017-02-27
WO2016014904A1 (en) 2016-01-28
MX2017000806A (en) 2017-05-01
CN110117273A (en) 2019-08-13

Similar Documents

Publication Publication Date Title
ZA201700652B (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
HRP20190039T1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1245260A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1246645A1 (en) Inhibitors of cyclin-dependent kinases
HRP20181650T1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PL3218378T3 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EP3347018A4 (en) Inhibitors of cyclin-dependent kinases
FI3302448T3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
EP3131900A4 (en) Heterocyclic kinase inhibitors
IL248789A0 (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
IL252560A0 (en) Heterocyclic derivatives and use thereof
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
PL3143032T3 (en) Novel derivatives of oxazaphosphorines and therapeutic uses thereof
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors